- Connect Biopharma Holdings Limited CNTB announced post hoc data analysis from the Phase 2b CBP-201 global trial in moderate-to-severe atopic dermatitis (AD).
- The data exhibited that CBP-201 led to rapid and sustained improvement in AD signs and symptoms across all four body regions, compared to the placebo.
- EASI subscores improved in all four body regions across 16 weeks of treatment.
- Improvements between 300 mg Q2W and Q4W were comparable. At Week 2, EASI decreased by -26.3% (head/neck), -26.4% (trunk), -21.6% (upper limbs), and -23.2% (lower limbs) for patients on CBP-201 300 mg Q4W treatment vs. -9.5% to -15.7% with placebo.
- At Week 16, EASI decreased further to -69.2% (head and neck), -72.1% (trunk), -64.2% (upper limbs), and -68.5% (lower limbs) vs. -21.2% to -49.1% with placebo (p<0.01 per region).
- Researchers also observed improvement for each classification of AD symptoms (signs): erythema, induration/papulation, lichenification, and excoriation, within each body region.
- Concurrently, the company also announced data from Stage 1 of the ongoing pivotal CBP-201 China trial in moderate-to-severe atopic dermatitis (AD), exhibiting rapid relief from symptoms.
- The study met primary and secondary endpoints, with mostly mild-to-moderate adverse effects reported.
- At 16 weeks, more patients treated with CBP-201 achieved an IGA score of 0-1 (clear or almost clear skin) and a 2-point IGA reduction than those on placebo (30.3% vs. 7.5%).
- 62.9% of CBP-201 patients achieved a 75% skin clearance (EASI-75), versus 23.4% in the placebo group and EASI-90 of (35.8% vs. 63.%).
- Price Action: CNTB shares are up 20.90% at $1.33 during the premarket session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
